BITI 7.00 Bio-Imaging Technologies to Join Russell Microcap Index
Jun 22, 2007 8:00:00 AM
Copyright Business Wire 2007
NEWTOWN, Pa.--(BUSINESS WIRE)--
Bio-Imaging Technologies, Inc. ("Bio-Imaging") (NASDAQ: BITI) today announced that it will join the Russell Microcap(TM) Index when the Russell Investment Group reconstitutes its family of US indices on June 22, according to a preliminary list of additions posted on www.russell.com.
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indices. Russell determines membership for its equity indices primarily by objective, market-capitalization rankings and style attributes.
Mark L. Weinstein, President and Chief Executive Officer of Bio-Imaging, said, "Inclusion in the Russell Microcap Index underscores our solid financial position and a growing recognition of Bio-Imaging by the investment community. We look forward to the increased visibility provided by our inclusion in the Russell Microcap Index and are grateful for the continued support of our investors and their confidence in our management team."
About Russell
Russell Investment Group aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products. With more than $200 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors. For more information on Russell indices, go to www.russell.com.
Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab in Newtown, PA, its European Core Lab in Leiden, The Netherlands and its recent acquisition of Theralys SA in Lyon, France. Through its CapMed division, Bio-Imaging provides the Personal HealthKey(TM) technology and the Personal Health Record (PHR) software allowing patients to better monitor and manage their health care information. Copies of Bio-Imaging Technologies' press releases and other information may be obtained through Bio-Imaging's web site at www.bioimaging.com.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.
Source: Bio-Imaging Technologies, Inc.
----------------------------------------------
Bio-Imaging Technologies
Inc.
Mark L. Weinstein
President & CEO
Ted I. Kaminer
CFO
267-757-3000
IR@bioimaging.com
or
Porter
LeVay & Rose
Inc.
Linda Decker
VP - Investor Relations
212-564-4700
or
Tom Gibson
VP - Media Relations
201-476-0322
AI
News 
Market Data 
Discover 
